Sequenom Inc

Sequenom — Investor Presentation (September 2012)

28 slides from Sequenom's investor presentation, Sep 12, 2012

  1. Slide 1: From Academic Research Through Translational Applications To Clinical Diagnostics

    From Academic Research Through Translational Applications To Clinical Diagnostics Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements xcept for historical information, matters set forth in this presentation, including statements regarding Sequenom’s plans, potential, opportunities, financial or other expectations, projections, goals, objectives, milestones, strategies, market growth, timelines, product p

  3. Slide 3: Investment Highlights

    Investment Highlights Large Potential Addressable Target Market MaterniT21 PLUS is a Leading Prenatal, Noninvasive Laboratory Developed Test with IP Protection • Clinical leader, first mover advantage, large and effective sales force and commercial infrastructure for growth Broad Prenatal Diagnostic

  4. Slide 4: Sequenom, Inc.

    Sequenom, Inc. Two operating segments: • Genetic Analysis - Sequenom, Inc. - Instrument, Reagents, Services for Genetic Analysis - San Diego, CA and Sales Offices US, EU and Asia • Molecular Diagnostics - Sequenom Center For Molecular Medicine (Sequenom CMM) - Clinical Diagnostic Service Laboratorie

  5. Slide 5: Genetic Analysis Business

    Genetic Analysis Business (mm) 2009 2010 2011 1H 2012 ** Good penetration of target markets • Translational and Basic Research • Agricultural Genomics • Pharmaceutical and Biotech Launched MassARRAY Analyzer 4 * in 2010 with improved margins Over 1,700 peer reviewed published articles on using Seque

  6. Slide 6: Molecular Diagnostics Product Portfolio

    Molecular Diagnostics Product Portfolio RetnaGene Age-related Macular Degeneration (AMD) LDT Sensi Gene Cystic Fibrosis Carrier Screening LDT Sensi Gene Fetal RHD Genotyping LDT MaterniT21 PLUS LDT Trisomy 21 (IVD) Ophthalmology Dx Research Development Launch Laboratory-Developed Test (LDT) by Seque

  7. Slide 7: Sequenom CMM Testing Volume

    Sequenom CMM Testing Volume FY 2011 vs YTD 2012 Samples Per Week of MaterniT21 PLUS * Partial year results are not necessarily indicative of full year or future performance All Laboratory-Developed Tests (LDTs) – (CF, RHD, AMD, T21+) MaterniT21 ™ PLUS LDT: FY 2011: 21,000 total samples billed 1H 201

  8. Slide 8: Status of Key Goals Established for 2012

    Sequenom, Inc. Status of Key Goals Established for 2012 Raise additional capital to support expansion of diagnostics business (H1) Expand European licensing partnerships (Q3) LifeCodexx launch Introduction of new RUO panels for MassARRAY platform (FY2012) Obtain issuance of Lo random sequencing pate

  9. Slide 9: Status of Key Goals Established for 2012 Sequenom CMM

    Status of Key Goals Established for 2012 Sequenom CMM Increase field sales force from 20 to 50+ 75+ (Q1/Q3) Publication of MaterniT21 PLUS T18/13 clinical study results (Q1) Complete AMD progression study (AREDS) (Q2) Increase throughput and reduce COGS for the MaterniT21 PLUS LDT (FY2012) Invoice a

  10. Slide 10: Key Driver for Sequenom Growth

    Key Driver for Sequenom Growth --

  11. Slide 11: MaterniT21 PLUS LDT

    MaterniT21 ™ PLUS LDT Description: A noninvasive laboratory developed test to identify pregnancies at increased risk for fetal trisomies: T21, T18 and T13 reported Performance: Detection rate for: T21: 99.1%* (210/212) T18: >99.9% (59/59) T13: 91.7% (11/12) No result rate 0.9%. Validated in large sc

  12. Slide 12: Market Leadership Advantage for MaterniT21 PLUS

    Market Leadership Advantage for MaterniT21 PLUS First to market/innovation (launch Oct 2011) Most experienced (27,000+ tests run) Strongest balance sheet ($98.6M cash and investments at 6/30/12) Largest sales force (~75 field reps nationwide) Greatest equipment capacity (>200,000 tests/year at 12 pl

  13. Slide 13: LDT Market Opportunities

    MaterniT21 ™ PLUS LDT Market Opportunities * National Center for Health Statistics, National Vital Statistics Reports; www.cdc.gov/nchs Other High-Risk ~140,000 High-Risk Age 35-49 ~ 610,000 Potential Available Market U.S. 2007 Total Births: ~ 4.3M *

  14. Slide 14: Market Penetration in High Risk U.S. Market

    Market Penetration in High Risk U.S. Market U.S. High Risk Births: ~750,000 Invasive Procedures ~200,000 SQNM Annualized Run Rate ~70,000

  15. Slide 15: LDT: Precision Proven in Large, Target Market Validation Studies

    MaterniT21 ™ PLUS LDT: Precision Proven in Large, Target Market Validation Studies Genet Med 1 Nov 2011 Genet Med 2 Mar 2012 Prenat Diagn 3 Online May 2012 In preparation In preparation 1. Palomaki GE, et al ., DNA Sequencing of Maternal Plasma to Detect Down Syndrome: An International Clinical Vali

  16. Slide 16: Peer-Reviewed Literature Basis for Sequenom CMM Laboratory-Developed Tests

    Peer-Reviewed Literature Basis for Sequenom CMM Laboratory-Developed Tests (LDTs)

  17. Slide 17: LDT: Ordered by Physician, Reported to Physician

    MaterniT21 ™ PLUS LDT: Ordered by Physician, Reported to Physician

  18. Slide 18: LDT: CLIA Quality Control & Outcome Metrics > 20,000 Patients

    MaterniT21 ™ PLUS LDT: CLIA Quality Control & Outcome Metrics > 20,000 Patients 68% 5% 24% 19% * Total equals greater than 100% as certain patients have multiple indications for testing

  19. Slide 19: LDT: CLIA Laboratory Experience: > 20,000 Patients

    MaterniT21 ™ PLUS LDT: CLIA Laboratory Experience: > 20,000 Patients

  20. Slide 20: Intellectual Property

    Intellectual Property ‘540 Lo Patent – U.S. ‘540 Lo Patent – Europe Other Relevant Prenatal Patents and Applications ‘181 Patent – Random Sequencing (MPSS) U.S. ‘181 Patent – Random Sequencing (MPSS) Europe Pending Issued Over 500 issued and allowed patents More than 330 pending patent applications

  21. Slide 21: LDT Process: Focus on COGS Reduction in 2012/2013

    MaterniT21 ™ PLUS LDT Process: Focus on COGS Reduction in 2012/2013 Sample Processing - Shipping and Sample Prep Automation Data Analysis - Enhanced Bioinformatics Sequencing - Increased Throughput, Faster Run Time Library Preparation - Automation and Simplification

  22. Slide 22: LDT Cost of Goods Sold

    MaterniT21 ™ PLUS LDT Cost of Goods Sold Expect to reach COGS unit goal of $500-600 by Y/E 2012 * Royalty obligation accrued on revenues recognized * Increased sample throughput (plexing) Flow cell/reagent enhancement Sample prep/process automation Collection tube shipment at ambient temperature Con

  23. Slide 23: 2012 Operational Updates

    2012 Operational Updates: 27,000 tests accessioned YTD in 2012 Growing orders by Maternal-Fetal Medicine specialists (> 25%) and the OB/GYN community Turn-around is now ~7 business days from initial 8-10 days Expanded prenatal sales force, now totaling ~75 active field sales reps and managers nation

  24. Slide 24: Cash vs. Accrual Accounting: Solid Test Adoption, Unpredictable Revenue in 2012

    Cash vs. Accrual Accounting: MaterniT21 ™ PLUS LDT Test #1 Costs booked Test billed Test #1 Cash payment received Test #2 Costs booked Test billed Test #2 Cash payment received Test #3 Costs booked Test billed Month Month xx Accrual Accounting Implemented Solid Test Adoption, Unpredictable Revenue i

  25. Slide 25: Reimbursement Environment: LDT

    Reimbursement Environment: MaterniT21 ™ PLUS LDT Initial emphasis with Private Insurers, receiving payment as out-of-network provider First signed contract with MultiPlan in early 2012 Additional regional contracts in process for 2012 Covered Lives of ~26 million (7/26/12) Source: NHDS 2008, Other i

  26. Slide 26: Financial Highlights ($ Millions)

    Financial Highlights ($ Millions) Note: Principal amount of the revolving credit facility is due May 31, 2014. The term loans mature on May 1, 2015. * Includes cash & marketable securities. Net proceeds from equity offering in January of 2012 increased cash balances by $58.5M. ** Cash burn includes

  27. Slide 27: Investment Highlights

    Investment Highlights Large Potential Addressable Target Market MaterniT21 PLUS is a Leading Prenatal, Non-Invasive Laboratory Developed Test with IP Protection • Clinical leader, first mover advantage, large and effective sales force and commercial infrastructure for growth Broad Prenatal Diagnosti

  28. Slide 28: Contact: Marcy Graham, Investor Relations

    Contact: Marcy Graham Senior Director, Investor Relations www.sequenom.com www.scmmlab.com ©2012 Sequenom, Inc. All rights reserved. Sequenom®, Sequenom CMM®, MassARRAY®, SensiGene® , MaternitT21™ PLUS and SEQureDx ® are trademarks of Sequenom, Inc. All other trademarks are the property of their res

Sequenom — Investor Presentation (September 2012) on 6ix